Etanercept for Crohn's Disease [3] (multiple letters)

New England Journal of Medicine

Volumn 350, Issue 8, 2004, Pages 840-

  Travers, Suzanne B ^a   Kupper, Thomas S ^b  

^a CENTOCOR INC   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; GASTROINTESTINAL AGENT; HYBRID PROTEIN; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; PLACEBO; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; CLINICAL TRIAL; CROHN DISEASE; DISEASE SEVERITY; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; ENTERITIS; HUMAN; LETTER; PRIORITY JOURNAL; PSORIASIS; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOGLOBULIN G; INFLAMMATORY BOWEL DISEASES; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 1142298488     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200402193500818     Document Type: Letter

References (0)